inclusion criteria: - adult volunteers to be vaccinated with the comirnatytm vaccine and to participate in the study, belonging to one of the following groups: - group of immunocompromised (15 participants per immunosuppression subgroup): - kidney transplant - extracorporeal dialysis - solid cancer under chemotherapy and / or radiotherapy - myeloma under chemotherapy - hematologic malignancies under chemotherapy - diseases treated with anti cd20 (or patients not treated at the time of the vaccine but who will be immediately after) - multiple sclerosis under anti cd20 (or patients not treated at the time of the vaccine but who will be immediately after) - common variable immune deficiency or other causes of severe hypogammaglobulinemia requiring chronic treatment with polyvalent immunoglobulin - malignant tumor under anti-pd1 or anti-pdl1 - people living with hiv - complicated type 2 diabetes (with micro and / or macroangiopathy) - group of non-immunocompromised subjects (controls, n = 75) - 60 people vaccinated with the comirnatytm - 15 people vaccinated with astra zeneca's vaxzevriatm for the first dose

inclusion criteria: - adult volunteers to be vaccinated with the comirnatytm vaccine and to participate in the study, belonging to one of the following groups: - group of immunocompromised (15 participants per immunosuppression subgroup): - kidney transplant - extracorporeal dialysis - solid cancer under chemotherapy and / or radiotherapy - myeloma under chemotherapy - hematologic malignancies under chemotherapy - diseases treated with anti cd20 (or patients not treated at the time of the vaccine but who will be immediately after) - multiple sclerosis under anti cd20 (or patients not treated at the time of the vaccine but who will be immediately after) - common variable immune deficiency or other causes of severe hypogammaglobulinemia requiring chronic treatment with polyvalent immunoglobulin - malignant tumor under anti-pd1 or anti-pdl1 - people living with hiv - complicated type 2 diabetes (with micro and / or macroangiopathy) - group of non-immunocompromised subjects (controls, n = 75) - 60 people vaccinated with the comirnatytm - 15 people vaccinated with astra zeneca's vaxzevriatm for the first dose